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Abstract 
Background 
Pseudoxanthoma elasticum (PXE) is characterized by skin (papular lesions), ocular 
(subretinal neovascularisation) and cardiovascular manifestations (peripheral artery disease), 
due to mineralization and fragmentation of elastic fibres in the extracellular matrix (ECM). 
Caused by mutations in the ABCC6 gene, the mechanisms underlying this disease remain 
unknown. The knowledge on the molecular background of soft tissue mineralization largely 
comes from insights in vascular calcification, with involvement of the osteoinductive 
Transforming Growth Factor beta (TGFβ) family (TGFβ1-3 and Bone Morphogenetic 
Proteins [BMP]), together with ectonucleotides (ENPP1), Wnt signalling and a variety of 
local and systemic calcification inhibitors. In this study, we have investigated the relevance 
of the signalling pathways described in vascular soft tissue mineralization in the PXE knock-
out mouse model and in PXE patients. 
Methods 
The role of the pro-osteogenic pathways BMP2-SMADs-RUNX2, TGFβ-SMAD2/3 and 
Wnt-MSX2, apoptosis and ER stress was evaluated using immunohistochemistry, mRNA 
expression profiling and immune-co-staining in dermal tissues and fibroblast cultures of PXE 
patients and the eyes and whiskers of the PXE knock-out mouse. Apoptosis was further 
evaluated by TUNEL staining and siRNA mediated gene knockdown. ALPL activity in PXE 
fibroblasts was studied using ALPL stains. 
Results 
We demonstrate the upregulation of the BMP2-SMADs-RUNX2 and TGFβ-2-SMAD2/3 
pathway, co-localizing with the mineralization sites, and the involvement of MSX2-canonical 
Wnt signalling. Further, we show that apoptosis is also involved in PXE with activation of 
Caspases and BCL-2. In contrast to vascular calcification, neither the other BMPs and TGFβs 
nor endoplasmic reticulum stress pathways seem to be perturbed in PXE. 
Conclusions 
Our study shows that we cannot simply extrapolate knowledge on cell signalling in vascular 
soft tissue calcification to a multisystem ectopic mineralisation disease as PXE. Contrary, we 
demonstrate a specific set of perturbed signalling pathways in PXE patients and the knock-
out mouse model. Based on our findings and previously reported data, we propose a 
preliminary cell model of ECM calcification in PXE. 
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Background 
Pseudoxanthoma elasticum (PXE; OMIM # 264800) is an autosomal recessive systemic 
connective tissue disease affecting the extracellular matrix (ECM) of multiple organs [1]. It is 
characterized by dermal (papular lesions in flexural areas), ocular (angioid streaks, subretinal 
neovascularisation and haemorrhage) and vascular symptoms (coronary and peripheral 
vascular disease) which result from mineralization and fragmentation of elastic fibres. PXE is 
caused by mutations in the ABCC6 (ATP-binding cassette subfamily C member 6) gene, 
encoding a transmembrane ATP driven organic anion transporter, the substrate of which is 
currently unknown. The biological mechanisms of ectopic mineralization in PXE, including 
the exact relationship with the defective ABCC6 transporter remain unclear [2]. Current 
knowledge on the molecular background of soft tissue mineralization largely comes from 
insights in vascular calcification (Figure 1). Murine models of calcified vasculopathies 
demonstrate that signalling pathways involved are those required for the physiological 
development of bone and cartilage, influencing gene transcription, apoptosis, matrix vesicle 
formation, endoplasmic and oxidative stress. Main protagonists are the osteoinductive 
Transforming Growth Factor beta (TGFβ) family (TGFβ1-3 and Bone Morphogenetic 
Proteins [BMP]), together with ectonucleotides (ENPP1), Wnt signalling and a variety of 
local and systemic calcification inhibitors, many of which have been previously associated 
with PXE, such as matrix Gla protein (MGP), osteocalcin (OC), bone sialoprotein (BSP or 
osteopontin), osteoprotegerin (OPG) and fetuin-A [3-9]. MGP is a protein belonging to the 
family of so-called “gla-proteins”, because of the presence of “gla-residues” which need to 
undergo gamma-carboxylation for activation of the protein. This carboxylation process is 
performed by the GGCX (gamma-glutamylcarboxylase) enzyme in the so-called ‘vitamin K 
(VK)-cycle’, as VK is an essential co-factor for this post-translational modification [10]. 
MGP serves as mineralization inhibitor via direct repression of bone morphogenetic protein-2 
(BMP2), an osteo-inductive member of the TGF-β family of growth factors [11-13], which 
has also been implicated in directing soft tissue calcification [14]. We and others have 
previously shown that MGP is abundantly present in calcified PXE tissues in its 
uncarboxylated or inactive form and that the loss of MGP repression on BMP2 results in an 
upregulation of BMP2 in the middermis of PXE patients [5]. The observation of low VK1 
serum levels in PXE patients was suggested as a contributing factor leading to this inefficient 
carboxylation of MGP. Besides local inhibitors, PXE patients were shown to have a 
deficiency of the systemic mineralization antagonist Fetuin-A [15]. Recently, the role of the 
ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENPP1 was confirmed as mutations 
in the encoding gene can also result in PXE [16,17]. 
Figure 1 Schematic representation of the pathways (1–10) involved in vascular soft 
tissue mineralization. Vascular calcification is the result of a transdifferentiation process of 
vascular smooth muscle cells (VSMCs) to chondrocyte-like or osteoblast-like cells [18]. (1) 
BMP2 and BMP4 induce osteogenic differentiation through SMAD dependent signal 
transduction. BMP2/4 ligands bind with BMP receptors BMPR-I and BMPR-II; BMPR-II 
then phosphorylates and activates BMPR-I. Phosphorylated BMPR-I subsequently 
phosphorylates SMAD1, SMAD5 and SMAD8 (SMAD1, 5, 8) which associate with SMAD4 
to form the heteromeric pSMAD1,4,5,8. This facilitates nucleation, where they regulate the 
pro-osteogenic runt-related transcription factor RUNX2 [19]. Downstream targets of RUNX2 
include osterix (OSX), alkaline phosphatase (ALPL or TNAP), osteopontin (OPN), 
osteocalcin (OC) and collagen type-1 (Col-1) [20]. (2) TGF-βs (1-2-3) bind to TGF-β 
receptor type I or II, resulting in phosphorylation of SMAD2/3, coupling with SMAD4 and 
translocation into the nucleus [21-23], where they trigger targeted gene expression of 
connective tissue growth factor (CTGF) [24-26]. (3) BMP7 activates endogenous 
SMAD1,5,8 and forms a SMAD1,4,5,8 complex, facilitating nucleation and stimulation of 
VSMC specific genes (SM-MHC, SM actin, MGP, Id-2). Through SMAD6 and SMAD7, 
BMP7 also inhibits BMP2 and TGF-β signalling [27]. (4) Elevated inorganic phosphate (Pi) 
enters the cell via sodium-dependent phosphate co-transporters PiT-1 and 2, resulting in 
downregulation of mineralization inhibitors, apoptosis (through downregulation of GAS6 and 
BCL-2, thus activating caspases), and upregulation of RUNX2 through ERK1/2 activation 
[28-30]. (5) MSX2 upregulates different Wnt receptors, causing stabilization of β-catenin, 
which after nucleation increases TCF-1/LEF-1 dependent gene expression. This in turn can 
upregulate MSX2 expression [31]. (6) DLX5 drives RUNX2 expression and osteogenic 
differentiation, and can abrogate osterix induction by BMP2. DLX5 also negatively regulates 
the activity of MSX2 [32]. (7) ER stress initiates a cascade of chaperone proteins leading to 
activation of caspases such as Caspase 12 and apoptosis (so-called unfolded protein response) 
[33]. (8) BMP2 can directly increase expression of ERK1/2, thus increasing RUNX2 
expression and SMC phenotypic transition toward osteochondro-progenitors [34]. (9) 
Oxidative stress and inflammatory mediators respond with higher BMP2/4 secretion in 
VSMCs calcification process [35,36]. (10) Tissue nonspecific alkaline phosphatase (TNAP or 
ALPL) has a major role both as a PPiase and as an ATPase/ADPase and thus participates in 
the calcification process by restricting the concentration of extracellular PPi, a calcification 
inhibitor. Nucleotide pyrophosphatase phosphodiesterase 1 (NPP1) works as a backup for 
PPiase and ATPase, especially in the absence of [27]. 
However, limited information is available on the key cellular pathways of soft tissue 
mineralization, the TGFβ superfamily-related signalling - its ligands (TGFβ1-3, BMPs), its 
receptors (TGFβR1/2, BMPRI/II) and its intracellular signal transducers (SMADs - Mothers 
Against Decapentaplegic homolog proteins) -, Wnt signalling, apoptosis or ER stress, in 
PXE. In the heart of Abcc6 −/−mice, the BMP responsive transcription factors Smad1/5/8 
were found to be upregulated, implying deregulation of BMP signalling pathways. Though no 
other tissues were examined, the authors concluded that further study of the BMP signalling 
axis may be of importance in the study of PXE [37]. The potential importance of these 
signalling pathways was recently endorsed by Sowa et al. demonstrating ectopic expression 
of RUNX2 in calcified cardiac tissue of the Dyscalc1 mice, in which an Abcc6 splice variant 
results in Abcc6 transporter deficiency [38]. These findings suggest that signalling pathways 
implicated in calcified vasculopathies may be relevant for PXE, though it may seem 
presumptuous to assume that their involvement is identical in a complex multisystem 
calcification disease such as PXE. In this study, we have investigated the relevance of the 
signalling pathways described in vascular soft tissue mineralization in the PXE knock-out 
mouse model and in PXE patients. We demonstrate perturbance of several but not all 
effectors of vascular mineralization. We have combined our results and literature data on 
PXE to propose a preliminary cell-based model of ECM mineralization in PXE as a starting 
point for cellular research in this complex disease. 
Methods 
Ethics statement 
This study was approved by the Ethical Committee of the Ghent University Hospital. 
Informed consent was obtained from all patients and the Declaration of Helsinki protocols 
were followed. 
Abcc6 KO Mice 
The mouse model for PXE has been developed by targeted ablation of the Abcc6 gene [39]. 
The mice were maintained in the Animal facility of the Department of Cell and Molecular 
Biology, John A. Burns School of Medicine, University of Hawai’i. These knockout mice 
recapitulate the histopathological and ultrastructural features of human PXE. In addition, a 
prominent mineralization of the connective tissue capsule surrounding the hair follicles in 
vibrissae of this mouse model has been observed. This feature has been proposed as an early 
biomarker of the overall mineralization process in PXE [9]. The IHC experiments in this 
study were performed on paraffin embedded tissues of the eyes (Bruch’s membrane) and 
whiskers of the Abcc6 −/−mice. 
PXE patients 
Dermal tissues and fibroblast cultures were obtained through full thickness skin biopsies in 
macroscopic skin lesions from clinically and molecularly confirmed PXE patients followed in 
the PXE Clinic of the Ghent Center for Medical Genetics. 
Fibroblasts of 8 PXE patients and 5 healthy age- and sex-matched controls were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% Fetal Calf Serum, 1% 
penicillin/Streptomycin, 1% Kanamycin, 1% non-essential amino acid and 0.1% fungizone. 
Cultures were maintained by refreshing media twice a week and incubated at 37°C (5% CO2). 
First, fibroblasts were grown in T25 cm2 flask; when 100% confluent, fibroblasts were 
spliced and transferred in T75 cm2 flask. When 100% confluent, cells were spliced and grown 
in 60 mm petri-dishes. Fully confluent 60 mm petri-dishes were scraped and centrifuged to 
extract the tissues and stored at −80°C. 
Histological analysis 
Alizarin red staining (ARS): Five µm sections from muzzle skin containing whiskers (or 
vibrissae) from Abcc6−/−mice and lesional skin sections from PXE patients were stained 
with 2% (pH 4.2, freshly prepared) ARS (Sigma-Aldrich, Belgium). To observe ARS in 
fibroblast cultures (n = 3), cells were fixed in 10% phosphate-buffered formalin, subsequently 
washed with PBS (pH 7.4) and stained with Alizarin Red solution (40 mM Alizarin Red-
Tris–HCl, pH 4.1) at room temperature (RT) for 10 min. After washing three times with PBS, 
cells were mounted with vectashield (Vectastain kit, Labconsult, CA). 
Alkaline phosphatase (ALPL) staining: To detect ALPL activity, control (n = 3) and PXE (n 
= 3) fibroblasts were cultured in an 8 well chamber slide, fixed with 0.4% cold 
paraformaldehyde (10 min.), rinsed with ALPL solution (100 mM Tris–HCl, pH 9.5, 100 mM 
NaCl, 10 mM MgCl2) and stained with a 1% BM Purple solution (Roche Molecular 
Biochemicals, Belgium) at 37°C (30 min.). After light microscopical evaluation (Zeiss, 
Germany), images were taken for all experiments using Axiovision Reflected Light 4.6 
software (Carl Zeiss MicroImaging, GmbH, Germany). 
Immunohistological analysis 
Immunohistochemistry (IHC) was performed on formalin-fixed and paraffin embedded 
whisker and eye tissues (5 µm) of Abcc6 KO mice and human dermal tissues prepared from 
lesional skin biopsies, using primary antibodies against BMP2 (Abcam, USA), pSMAD1 
(Abcam, USA), pSMAD2 (Cell Signalling Technology, The Netherlands), pSMAD4, 5 
(Abcam, USA) and pSMAD8 (Santa Cruz Biotechnology, Inc., Germany), pSMAD1-5-8 (an 
antibody recognizing SMAD1 only when dually phosphorylated at Ser463 and Ser465, as 
well as phosphorylated SMAD5 and SMAD8; Abcam, USA), RUNX2 (M70, Santa Cruz 
Biotechnology, Inc., Germany), CTGF (Abcam, UK), Caspase 3 (BIOKE, Cell Signalling 
Technology, The Netherlands) and pERK1/2 (Abcam, UK). Labelling was always performed 
on slides adjacent to those with proven mineralization on Alizarin Red staining (Sigma-
Aldrich, Belgium). Each labelling was done on 5 (patients, mouse tissues) or 3 (human 
controls) slides. Briefly, antigens were unmasked after deparaffinization, using 1 mM EDTA 
(pH 8, boiled for 20 min.), cooled down (30 min. at RT) and subsequently antibody binding 
steps were performed by washing sections in distilled water (3 × 5 min.), 3% hydrogen 
peroxide (1 × 10 min.), distilled water (2 × 5 min.) and in TBS-T (1 × 5 min.). Sections were 
blocked with 5% BSA (in TBST) for 1 h. at RT. After removal, sections were incubated with 
primary antibodies (1:100 dilution in TBST + 5% Bovine Serum Albumin) overnight at 4°C 
in a moist chamber. After washing, the secondary antibody (Rabbit IgG) was added 
according to manufacturer’s recommendation (Vectastain kit, Labconsult, CA). After 
washing, tissue sections were incubated with ABC reagent (45 min. at RT; Vectastain kit, 
Labconsult, CA) and subsequently treated with AEC reagent (30 min.) or DAB (Vectastain 
kit, Labconsult, CA). Slides were washed mounted with cover slips. Tissue sections were 
evaluated using light microscopy (Zeiss, Germany). Images were taken using Axiovision 
Reflected Light 4.6 software (Carl Zeiss Microlmaging, GmbH, Germany). 
Fluorescent immunohistochemistry 
To detect co-localization of RUNX2-Caspase 8, fluorescent immunohistochemistry was 
performed on PXE skin tissue (n = 5). Tissue sections were deparaffinized, and blocked with 
5% BSA (1 h), incubated with an anti-rabbit polyclonal RUNX2 antibody (1:200; M 70, 
Santa Cruz Biotechnology Inc., Germany) and an anti-mouse monoclonal Caspase 8 antibody 
(1:200; BIOKE, Cell Signalling Technology, The Netherlands) for 2 hrs. After removal of the 
primary antibody, the sections were incubated with the secondary antibody Cy3 (anti-rabbit, 
1:100; GE Healthcare, Germany) and Alupa 488 (anti mouse, 1:100; Life Technologies 
Europe) for 1 h. 
All tissues were mounted with vectashield with DAPI (Vectastain kit, Labconsult, CA) and 
images were taken under the fluorescent microscope (Axioplan 2 Imaging, Zeiss, Germany). 
Gene expression quantification by qPCR 
qPCR analysis was performed for key genes involved in the BMP2/BMP4-SMADs-RUNX2 
signalling pathway (RUNX2, BMP2, BMP4, SMAD1, SMAD4, SMAD5, SMAD8), the 
downstream RUNX2 target gene Osterix and ALPL, genes in the TGFβ signalling pathway 
(TGFβ-1, TGFβ-2, TGFβ-3, SMAD2, SMAD3 and CTGF), genes of the MSX2-Wnt pathway 
(MSX2, DLX5, LEF-1, TCF-1 and β-catenin), the inorganic phosphate transporter PiT-1, 
genes involved in apoptosis pathways (P21, GAS6, BCL-2, Caspase3), and genes for 
endoplasmic reticulum stress (CHOP, BIP, XBP1, IRE1, ATF4, ATF6, GAD34, JNK, XBP-
S). RNA was isolated from fully confluent fibroblasts using the RNeasy® kit (Qiagen, 
GmbH, Germany) according to manufacturer’s recommendation. To purify the RNA from 
any DNA that may be present, it was incubated with DNase (15 min. at RT). Concentration 
of total RNA was measured via the DropSense-96 multichannel spectrophotometer (Micronic 
North America, USA). cDNA was prepared from 2 µg of RNA using the iScript cDNA 
synthesis kit (Bio-Rad Laboratories, CA) and diluted 10-fold. qPCR was performed on 
control (n = 5) and PXE fibroblasts (n = 8) using HPRT1 (hypoxanthine phosphoribosyl 
transferase 1) and YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta isoform) as reference genes and the FastStart Universal Probe Maser 
Mix (Roche Applied Science, GmbH, Germany) in the Roche-LightCycler®480 real-time 
PCR system (Roche Applied Science, Belgium). qPCR primers are listed in Additional file 1: 
Table S1. Real time PCR data were analysed via the qbasePLUS software (Biogazelle, 
Belgium). 
In situ cell death detection 
In vitro evaluation of fibroblast cell death was performed via the in situ cell death detection 
(TUNEL - Tdt-mediated dUTP Nick-End Labelling) kit (Roche Diagnostics, GmbH, 
Germany). PXE fibroblasts were grown in 75 cm2 flask until 100% confluent. Concentration 
of the cells/ml was determined using an automated cell counting machine (Cellometer®auto 
T4, Nexcelom Bioscience, USA). Forty thousand cells per well were distributed on an 8 well 
plate. After 2 days, cells were washed with PBS (pH 7.4). Cells were stained with the 
TUNEL kit according to the manufacturer’s protocol after 24, 72 and 120 hrs. respectively. 
Percentage of cell death was counted under fluorescent microscope (Axioplan 2 imaging, 
Zeiss, Germany). For each cell culture (n = 6 for patients and 5 for controls), 10 microscopic 
fields were evaluated. 
RUNX2 siRNA transfection 
To evaluate the expression of RUNX2 at different time points (24, 48 and 72 hrs.) after 
siRNA transfection, 2 × 105 PXE fibroblasts (n = 6 cultures) were seeded in 6 well plates. 
After 24 hrs. cells were transfected with 6 µl (2 µM) of RUNX2 siRNA (sc-37145, sc-36868, 
sc-29528, Santa Cruz Biotechnology, Inc, Europe) or scrambled RNA (sc-37007, Santa Cruz 
Biotechnology, Inc, Europe) according to the manufacturer’s recommendations. Expression 
of RUNX2 after siRNA transfection was evaluated by qPCR (using primer sc-37145-PR, 
Santa Cruz Biotechnology, Inc, Europe) after 24, 48 and 72 hrs. (n = 2 cultures) TUNEL 
assay was performed as described above, respectively at 24, 48 and 72 hrs. after siRNA 
transfection (n = 6 cultures). 
Statistical analysis 
All data were analysed using the statistical software S-PLUS 8 (Insightful, Washington). 
Normality distribution of the data was evaluated by the Kolmogorov-Smirnov test. 
Differences between groups were compared using the one-sample t-test. Significance was 
considered at a confidence level of 0.95 and p < 0.05. 
Results 
The BMP2-SMADs-RUNX2 pathway is upregulated in human and murine 
PXE 
One of the most important pathways in vascular calcification involves BMP2-SMADs-
RUNX2 signalling, as RUNX2 is considered a master regulator of mineralization. To study 
the relevance of this pathway in PXE, first IHC staining of key proteins of this pathway was 
performed on the vibrissae and eyes of the Abcc6 KO mouse. Labelling for BMP2, 
pSMAD1, pSMAD4, pSMAD5, pSMAD8, pSMAD1-5-8 and RUNX2 revealed increased 
expression in the connective tissue capsule around the whiskers and in Bruch’s membrane of 
the eye compared to the wild type. These labellings co-localized with mineralization foci as 
seen on Alizarin Red stains (Figure 2). Subsequently, identical IHC stains were performed on 
human PXE dermis, which revealed identical results for all proteins. Positive staining in the 
human samples was confined to the mid-dermal skin area of elastic fibre mineralization 
compared to no staining in controls (Figure 3, A-G). 
Figure 2 Staining results for the BMP2-SMADs-RUNX2 pathway in whisker and eye 
sections from the Abcc6 KO mouse (×10). Negative controls are shown in the first column 
(A, E, I, M, Q, U, Y). Alizarin Red stainings confirms profound calcification in the 
connective tissue capsule of the whiskers (B, F, N, R, V and Z) and Bruch’s membrane of the 
eye (J). Immunohistochemical staining of adjacent slides with antibodies against respectively 
Bmp2 (C), Runx2 (G, K), pSmad4 (O), pSmad5 (S), pSmad8 (W) and pSmad1/5/8 (Aa), 
shows positive staining for all, co-localizing with the mineralization foci. Arrowed areas of 
positive staining have been magnified (×20). Scale bar = 100 µm. n = 5 each. 
Figure 3 Immunohistochemical labelling results of the SMAD-RUNX2 pathway in 
human PXE skin (n = 5 each) and fibroblasts (n = 8 each) compared to controls (n = 3 
each) (×10). The top-left panel shows absence of staining in controls (A), positive middermal 
staining for Alizarin red (B) and RUNX2 (C) in PXE skin. The top-right and middle two 
panels (D to H) depicts staining for pSmad4 (D), pSmad5 (E), pSmad8 (F) and pSMAD1/5/8 
(G) with positive labelling in the middermis of PXE patients compare to no labelling in the 
negative controls (inserts). The lower panel reveals positive labelling for Alizarin Red (J, K) 
and ALPL (L, M) in PXE fibroblast cultures (n = 3) compared to controls (n = 3) (I, L). 
Areas marked with asterisk are enlarged (×40). Scale bar = 100 µm. 
qPCR experiments performed for RUNX2, BMP2, BMP4, SMAD1, SMAD4, SMAD5, 
SMAD8, Osterix and ALPL confirmed a significant upregulation of RUNX2, BMP2, 
SMAD1, SMAD4, SMAD5, SMAD8 and ALPL in PXE fibroblasts compare to healthy 
controls (Figure 4), whereas expression of BMP4 and Osterix remained same as control. 
ALPL, one of the target genes of RUNX2, encodes the enzyme alkaline phosphatase (ALPL) 
which is an inducer of mineralization and showed the highest upregulation compared to 
controls (more than 3-fold; p < 0.05), whereas RUNX2 showed a more than 2-fold increase in 
expression (p < 0.05). The ALPL upregulation was also demonstrated on fibroblast cultures 
of PXE patients, where staining for Alizarin Red and ALPL showed positive labelling for 
both in PXE cells compared to controls (Figure 3, H-M). 
Figure 4 Relative expression of components of BMP2-SMADs-RUNX2 signalling 
including RUNX2, BMP2, BMP4, SMAD1, SMAD4, SMAD5, SMAD8, Osterix, and 
Alkaline Phosphatase (ALPL). Relative expression is shown in human PXE fibroblasts and 
control cells. A significant upregulation of all genes except BMP4 and Osterix was observed 
compared to controls. (n = 8 and 5 for patients and controls respectively). * p < 0.05. 
MSX2 expression is influenced by increased BMP2 and activates LEF-1/TCF-
1 transcription 
Besides SMADs-RUNX2 signalling, BMP2 can also upregulate MSX2. The expression of 
MSX2 was indeed significantly upregulated in PXE fibroblast compared to health controls 
(Figure 5). This was further corroborated by a decreased DLX5 expression, a known 
repressor of MSX2. In vascular calcification, MSX2 overexpression stimulates nuclear 
localisation of β-catenin, thus activating transcription of LEF-1 and TCF-1. Indeed, qPCR 
experiments reveal that expression of LEF-1 and TCF-1 was upregulated in PXE fibroblasts 
compared to controls, while β-catenin was expressed within normal limits (Figure 5). 
  
Figure 5 Relative expression of mediators in MSX2-Wnt signalling (MSX2, DLX5, LEF-
1, TCF-1 and β-catenin). qPCR reveals a marked upregulation of MSX2, LEF-1 and TCF-1 
as well as significant downregulation of DLX5 in human PXE fibroblasts compared to 
control cells. β-catenin is not differentially expressed in PXE fibroblasts. (n = 8 and 5 for 
patients and controls respectively).* p < 0.05. 
Human and murine PXE manifest increased TGFβ-2 signalling 
qPCR expression analysis of the three ligands of the TGFβ family - TGFβ-1, TGFβ-2, TGFβ-
3 - demonstrated increased expression of only TGFβ-2, while the others were within normal 
limits (Figure 6). After binding to a type II receptor dimer, TGFβ-2 is mediated by 
pSMAD2/3 and CTGF. To further confirm increased activity of TGFβ-2, qPCR of the critical 
downstream SMAD2, SMAD3 and CTGF gene in human PXE fibroblasts, and 
immunohistochemistry of critical mediators on murine and PXE tissues were performed. 
These experiments confirmed increased expression of the TGFβ-2 downstream signalling 
mediator CTGF (Figure 6). The expression of SMAD2 and SMAD3 was not significantly 
different compared to controls (Figure 6). Positive staining, co-localizing with mineralization, 
of pSMAD2 and CTGF was demonstrated in the PXE middermis (Figure 7, G-I and M-O 
respectively), and only pSMAD2 but not CTGF in the vibrissae and eye of the PXE KO 
mouse, compared to absent staining in controls (Figure 7, A-F and J-L respectively). 
Figure 6 qPCR result for markers involved in TGFβ signalling pathway (TGFβ-1, 
TGFβ-2, TGFβ-3, SMAD2, SMAD3 and CTGF). While relative expression of TGFβ-1 and 
−3 are normal, upregulation of TGFβ-2 and CTGF can be seen in human PXE fibroblasts 
compared to control cells. (n = 8 and 5 for patients and controls respectively). * p < 0.05 
Figure 7 Immunohistochemical labelling of key mediators of TGFβ-2 signalling in 
whisker and eye sections from the abcc6 knockout mouse (and skin tissues from PXE 
patients (×10). Alizarin Red staining visualizes calcification in the whiskers (A, J), Bruch’s 
membrane of the eye (D) and mid-dermis of the skin tissues (G, M). Immunohistochemical 
staining of adjacent slides with antibodies against pSMAD2 (B, E, H, arrowed) and CTGF 
(N, asterisk), show positive staining, co-localizing with the mineralization foci. In the 
whisker sections of the mouse model, no CTGF staining could be observed (K). Staining of 
wild-type whisker (C, L), eye (F), and human skin tissues (I and O) did not show any 
staining. (n = 5 each). Scale bar = 100 µm. 
Increased apoptosis in PXE tissues is only partially mediated by RUNX2 
Apoptosis is considered an important mechanism in soft tissue mineralization. We evaluated 
the presence of apoptosis in PXE fibroblast cultures using a TUNEL assay, light and 
fluorescent IHC. DAPI staining revealed the nuclear diameter to be smaller in PXE 
fibroblasts compared to controls (Figure 8). After 72 hrs., TUNEL staining showed 3× more 
apoptosis compared to controls (2.08% and 0.69% respectively, p < 0.05) (Figure 8; 
Additional file 2: Figure S2). This staining did not always co-localize with the nuclear DAPI 
labelling, but was present in the cytoplasm of the cells (Figure 8; Additional file 3: Figure 
S3). Caspase 3 and Caspase 8 - both critical executioners of apoptosis -, were used as 
biomarkers for immunohistochemical evaluation of apoptosis [40]. IHC labelling of caspase 3 
on murine whiskers and eye showed positive stains co-localizing with mineralization foci 
(Figure 9, A-D). 
Figure 8 Analysis of apoptosis by TUNEL staining in human fibroblasts (n = 6) 
compared to control cells (n = 5) (×20). Counter staining was performed using DAPI 
nuclear staining and pictures were taken using DAPI (upper row), FITC (fluorescein 
isothiocyanate; middle row) and Merged (lower row) filters. Results are shown for a positive 
and negative control (A, B), healthy control fibroblasts (C), PXE fibroblasts (D) and PXE 
fibroblasts transfected with RUNX2 siRNA respectively 24 (E), 48 (F) and 72 hours (G) 
following transfection. PXE fibroblasts show smaller nuclei on the DAPI stain and increased 
TUNEL staining in the cytoplasm of fibroblasts compared to controls, reflecting a three-fold 
increase of apoptosis (2,08% vs 0.69% respectively, p < 0.05). Twenty-four and 48 hours 
post-transfection with RUNX2 siRNA, a decrease of apoptosis can be seen, whereas after 72 
hours no difference can be observed compared to untreated PXE fibroblasts. Scale bar = 20 
µm 
Figure 9 Immunohistochemical staining results for Caspase 3 and Caspase 8. Upper 
panel: Staining is performed on whisker and eye sections from the Abcc6 knockout mouse 
(A-D, ×10) and human skin (E, F, ×20). Alizarin Red stains was used to localize 
mineralization (A, C). Positive staining for Caspase 3 is obtained on murine whiskers and eye 
(B, asterisk; D, arrow), co-localizing with ectopic mineralization. In human PXE dermis, 
Caspase 3 stains positive in the middermis (E, asterisk), while no staining is noted in controls 
(F). Scale bar = 100 µm. Lower panel: Fluorescent immunohistochemistry for Caspase 8 and 
RUNX2 confirms co-localisation in PXE skin (J, white arrow). DAPI nuclear staining (G). 
Merged RUNX2-DAPI image ((H, green fluorescence indicates RUNX2 staining, arrow) and 
merged Caspase 8-DAPI image (I, red fluorescence indicates Caspase-8 staining, arrow). (n = 
5 each). Scale bar = 20 µm. 
Several signal transduction components have been attributed pro-apoptotic properties. 
RUNX2, P21, GAS6/BCL-2 and PiT-1 have all been involved in apoptosis-induced vascular 
calcification. Besides the upregulation of RUNX2 and GAS6, and downregulation of BCL-2, 
none of other mediators were found to show a significantly different expression pattern in 
PXE fibroblasts compared to controls (Figure 10). As also the Unfolded Protein Response 
(UPR), a cellular stress response originating from the ER, was shown to initiate apoptosis in 
vascular mineralization by inducing caspases, we evaluated several ER stress markers 
(CHOP, BIP, XBP1, IRE1, ATF4, ATF6, GAD34, JNK, XBP-S) in PXE fibroblasts but 
found none to be significantly different compared to healthy controls (Figure 11). 
Figure 10 qPCR result for mediators of apoptosis reported in vascular soft tissue 
mineralization (PiT-1, P21, BCL-2 and GAS6). Relative expression shows a significant 
downregulation of BCL-2 and upregulation of GAS6 in human PXE fibroblasts compared to 
control cells. (n = 8 and 5 for patients and controls respectively). * p < 0.05. 
Figure 11 qPCR results for genes involved in UPR dependent ER-stress and apoptosis 
including CHOP, BIP, XBP1, IRE1, ATF4, ATF6, GAD34, JNK, XBP-S. Relative 
expression is shown in human PXE fibroblasts and control cells. No significant change in 
expression of any gene is observed. (n = 8 and 5 for patients and controls respectively). * p < 
0.05. 
As RUNX2 was differentially expressed in PXE and to confirm its presence in the foci of 
apoptosis, we performed fluorescent IHC co-labelling with Caspase 8, confirming co-
localisation of both antibodies (Figure 9, G-J). To further evaluate the contribution of 
RUNX2 to apoptosis, a siRNA experiment was performed to knock-down RUNX2 
expression. Expression levels were downregulated by 67% after 24 hrs., diminishing to 51% 
and 31% after 48 and 72 hrs. respectively compared to cells treated with siRNA and untreated 
cells (Additional file 4: Figure S4). As TUNEL staining for apoptosis in PXE fibroblasts 
tends to have the highest yield after 72 hours, we mainly focused at the 48 h. time frame 
where there was still more than 50% downregulation of RUNX2. TUNEL staining on siRNA 
transfected fibroblasts showed a visual decrease of apoptosis after 24 and 48 hrs., which 
could not be seen anymore after 72 hrs. (Figure 8). Quantification of apoptosis in the 
transfected fibroblasts showed a reduction of 13 to 20% in the first 24 to 48 hrs., but with 
variable results between cell cultures (Additional file 5: Figure S5). 
pERK1/2 activation in PXE may be due to BMP2 effect 
RUNX2-dependent transcription can also be regulated through the MEK/ERK pathway, 
either via BMP2 and/or PiT-1. We observed upregulation of pERK1/2, co-localizing with the 
calcified regions of both human PXE skin (middermis) and murine whiskers (Figure 12). 
PIT-1 expression was within normal limits (Figure 10). 
Figure 12 Immunohistochemical staining results for pERK1/2 (×10). Staining is 
performed on whisker from the Abcc6 knockout mouse (A-C) and PXE skin tissues (D-F). 
Alizarin Red stains was used to localize mineralization (A and D). Positive staining for 
pERK1/2 is obtained on murine whisker (B, arrow) and PXE skin (E, asterisk), co-localizing 
with mineralization. The pERK1/2 staining being broader than the mineralization staining 
could represent the active mineralization process where pERK1/2 expression precedes 
calcification. No staining is noted in control whisker (C) and control skin tissue (F). (n = 5 
each). Scale bar = 100 µm. 
Discussion 
Soft tissue mineralization is a complex process resulting from perturbation of a delicate 
interplay of developmental cues, protein signalling, transcription factors and their regulators. 
It is involved in both orphan and common disorders, leading to significant morbidity and 
mortality. Though still incompletely understood, important progress has been made in 
unravelling the signal transduction pathways leading to ectopic calcification. For this, 
vascular calcification has often been used as a model, in which the knowledge of cellular 
signalling resulted in improved understanding of the disease and novel therapeutic 
approaches [41,42]. Among orphan diseases, pseudoxanthoma elasticum is often considered a 
paradigm for ectopic mineralization disorders [43]. The pathophysiology of elastic fibre 
mineralization in PXE has so far remained unclear, though several mechanisms have been 
suggested to be involved, including chronic oxidative stress, an unidentified serum factor and 
deficiency of circulatory and local mineralization inhibitors [5,44]. Thus far, the data on 
cellular events in PXE are limited, restricted to specific tissues such as the heart and 
performed only in animal models [45]. It is unclear if and to what extent cellular mechanisms 
involved in vascular calcification are relevant in a multisystem mineralization disease such as 
PXE and more specifically in PXE patients. As it was recently demonstrated that these 
patients present a rather specific vasculopathy, differing from age-related atherosclerosis, it 
would seem presumptuous to automatically extrapolate the knowledge of calcified 
vasculopathies to PXE [16,46]. The pathobiological mechanisms in vascular calcification can 
be divided into two broad categories: induction of osteogenesis and loss of inhibitors of 
mineralization. Previous studies have already shown that several local and systemic 
calcification inhibitors, such as MGP and Fetuin-A, are functioning inadequately in PXE 
[5,15]. For the induction of an osteochondrogenic phenotype, the contribution of TGFβ 
signalling, BMPs-SMADs-RUNX2 signalling, Wnt-MSX2 signalling, apoptosis, oxidative 
stress and ER stress are well appreciated in calcified vasculopathies [3-9]. In this study, we 
wanted to assess which of these signalling pathways, if any, are perturbed in the PXE murine 
model and in PXE patients. 
The TGFβ superfamily consists of a large number of members (TGFβs, activins, inhibins, 
nodals, anti-mullerian hormone and BMPs) involved in various biological processes such as 
cell proliferation, differentiation, migration, adhesion, apoptosis and ECM production 
[47,48]. In ectopic mineralization, particularly BMPs and TGFβs have been attributed a 
prominent role [49]. BMP2 and BMP4 are important propagators of ectopic mineralization in 
vessels through a concerted action with SMADs, and downstream key osteogenic 
transcription factors including RUNX2 (or Cbfa1), MSX2 and osterix (OSX) [40,50,51]. 
They can induce osteoblast differentiation in a variety of vascular cells [49]. BMP7 has been 
shown to inhibit vascular calcification [52]. Although Mungrue et al. described an 
upregulation of BMP4 in cardiac tissue of the Abcc6−/−mouse [37], we could not confirm 
involvement of BMP4 in PXE, though a tissue-specific effect cannot be fully excluded [53]. 
Comparably, BMP7 activity was also within normal limits in PXE, but BMP2 was 
considerably overexpressed in the whiskers and Bruch’s membrane of Abcc6 KO mice as 
well as in the mid-dermis and fibroblasts of PXE patients, co-localizing with the elastic fibre 
mineralization. BMP2 activity is regulated by MGP, which in its active, carboxylated form 
can prevent BMP2 to interact with its receptor [54]. The excess of uncarboxylated MGP in 
PXE may thus contribute to the upregulation of BMP2, though it is not excluded that other 
mechanisms, such as epigenetic changes, are also involved [20]. 
Though BMP2 is a crucial mediator of vascular calcification, its downstream affects are 
achieved through the upregulation of RUNX2, MSX2 and OSX [49-51]. Increased 
immunostaining of pSmad1, pSmad4, PSmad5, pSmad8 and pSmad1-5-8 and RUNX2 in 
PXE and Abcc6−/−murine tissues confirms that in PXE a coordinated activation of the 
BMP2- SMADs-RUNX2 signalling pathway occurs. RUNX2 is considered the master 
regulator of osteogenesis, although the gene is not osteoblast-specific [53]. Its upregulation 
has been observed in calcified vasculopathies, together with MSX2 and OSX, confirming its 
role in soft tissue mineralization, where it induces VSMC to acquire an osteogenic phenotype 
[20,54-56]. This osteogenic differentiation is obtained through induction of ALPL activity 
and expression of bone matrix protein genes OC, Col 1, and BSP [54,57]. Similar changes 
could be seen in PXE fibroblasts, with increased ALPL expression on qPCR and increased 
ALPL activity in human cultured fibroblasts. ALPL promotor activity may also be stimulated 
in a RUNX2-independent manner by DLX5 (Distal-less homeobox 5), but little DLX5 
activity could be seen in PXE cells excluding this regulatory mechanism [58]. The mRNA 
expression of ALPL being considered a reliable method to determine BMP2-induced 
osteogenic differentiation of cells, this suggests that PXE fibroblasts adopt a gene expression 
profile similar to osteoblasts. It is also known that other target genes of RUNX2, such as OC 
or BSP, are abundantly present in PXE tissues [5,8]. Interestingly, RUNX2 has a dual effect 
on BSP. While normally inducing an overt BSP overexpression, RUNX2 has a tendency to 
decrease this BSP expression when upregulated itself. This might explain the observation of 
Contri et al. that BSP, though present, was significantly less abundant in PXE tissues 
compared to other pro-mineralizing proteins [21]. 
Besides induction by BMP2-SMADs, RUNX2-dependent transcription can also be regulated 
through the MEK/ERK (Extracellular Signal Regulated Kinases) pathway [59]. In vascular 
calcification, this is believed to pass through activation (phosphorylation) of ERK1 and 
ERK2, which can be achieved by both BMP2 and the phosphate transporter PiT-1. Though 
PXE tissues showed overexpression of pERK1/2, expression levels of PiT-1 were normal. 
Together with the normal phosphate levels in PXE patients, this excludes PiT-1 mediated 
ERK1/2 activation in PXE, but rather points towards an effect of BMP2. In epithelial cells, 
ERK1/2 activation has been shown to be precipitated by calcium influx [60]. It can thus not 
be excluded that the increased calcium in cultured PXE fibroblast, seen on Alizarin Red 
labelling, may serve as a positive feedback loop for ERK1/2 activity [61,62]. 
A second downstream mediator of BMP2 is MSX2, a transcription factor which promotes 
cardiovascular calcification by stimulating canonical Wnt signalling [31]. MSX2 induces 
nuclear stabilization of β-catenin resulting in a positive feedback of MSX2 expression and in 
the activation of TCF-1/LEF-1 transcription [31]. The upregulation of MSX2 and TCF-
1/LEF-1 in PXE cells demonstrates involvement of MSX2-Wnt signalling in PXE. The 
diminished expression of DLX5, an important negative regulator of MSX2-Wnt signalling, 
may also contribute to MSX2 overexpression in PXE. Suppression of DLX5 is well-known in 
several embryological mechanisms. Though the precise mechanisms are ill-defined, the role 
of transcription factors and epigenetic factors such as microRNAs has been documented and 
may be tissue-specific [63,64]. The clinical importance of Wnt signalling has been shown for 
many disorders, where Wnt effectors can serve as susceptibility genes or modifiers [65]. The 
involvement of canonical Wnt signalling in PXE should thus encourage us to study Wnt-
related pathways further. 
The role and regulation of the third mediator of BMP2, OSX, is incompletely understood. 
OSX is a member of the Sp1 transcription factor family and plays an essential role in bone 
formation and osteoblastogenesis [66]. In soft tissue mineralization, OSX has been attributed 
an important role in the transdifferentiation of smooth muscle cells into osteoblasts. Initially 
thought to function downstream of RUNX2, OSX expression in osteoblasts was shown to be 
regulated by RUNX2-dependent and -independent mechanisms which are not necessarily 
simultaneously active [67]. Several factors such as OC, PTH, SP1 and DLX5 can influence 
OSX activity [68]. In PXE fibroblasts, OSX is not upregulated. The lack of OSX 
overexpression might explain why PXE fibroblasts, though they show an osteoblast gene 
expression profile, do not transform morphologically into osteoblasts. 
The different TGFβ ligands (TGFβ-1, TGFβ-2, TGFβ-3) form a second group of TGFβ 
superfamily members which are implicated in vascular calcification [48]. TGFβ signalling in 
the vasculature is predominantly dependent on the activation of any of two type 1 receptors, 
Alk5 (TGFBR1) and Alk1 (ACVRL1), and signal transduction through activation of SMADs 
[69,70]. Among TGFβ ligands, TGFβ-1 is most frequently involved and promotes aortic 
smooth muscle cell calcification in culture, increases nodule formation in calcifying vascular 
cells in vitro, and is present in calcified aortic cusps [71-73]. Though TGFβ has already been 
suggested to be involved in PXE by Jiang et al., who reported that ABCC6 promoter activity 
can be modulated by several cytokines including TGFβ [74], it was somewhat unexpected to 
find only overexpression of TGFβ-2 in PXE fibroblasts, while expression of the other ligands 
(TGFβ-1 and TGFβ-3) remained the same as in controls. TGFβ-2 is expressed in the VSMCs 
of calcified arteriosclerotic arteries, induces chondrogenic differentiation of mesenchymal 
stem cells and induces calcifying activity in the human trabecular meshwork cells [75], but 
nearly always together with and less than TGFβ-1. Solitary TGFβ-2 overexpression seems to 
be unique in soft tissue mineralization diseases. Interestingly, isolated TGFβ-2 
overexpression was found in models of choroidal neovascularisation, a complication often 
seen in PXE patients [76]. Further, the observed increased level of MMP2 and MMP9 in PXE 
serum may also reflect TGFβ-2 activity, as it has a pivotal role in activating both 
metalloproteases [77-79]. Involvement of TGFβ-2 in PXE was further confirmed by 
increased expression of its downstream effectors pSMAD2, pSMAD4 and CTGF 
(Connective Tissue Growth factor) [80,81]. CTGF is considered a mediator of TGFβ 
signalling in fibroblasts. In adult skin, CTGF is normally not expressed, unless induced for 
example during wound healing. The absence of CTGF labelling in the murine whiskers and 
eye may reflect a physio-immunological difference in between human and mice, rather than 
an actual difference in murine and human PXE pathogenesis. 
Besides BMP2/TGFβ and Wnt signalling, also oxidative stress, endoplasmic reticulum stress 
and apoptosis can play a role in soft tissue calcification. PXE fibroblasts are well known to 
suffer mild chronic oxidative stress [82]. For all signalling pathways which are perturbed in 
PXE, a potential influence of reactive oxygen species (ROS) has been documented. There is 
some indication that BMP signalling may be mediated through ROS function and signalling 
[83]. ROS are able to induce both BMP2-RUNX2 signalling and MSX2-Wnt signalling, thus 
causing soft tissue calcification [84-86]. ROS-induced calcification was found to be retracted 
in RUNX2 knock-down cells, suggesting it to be RUNX2 dependent [87]. However, ROS has 
also been documented to influence those mediators which were normal in PXE, such as 
BMP4 [88]. This duality makes it less convincing that the contribution of ROS is a truly 
significant in PXE, though this remains difficult to assess. 
The mechanisms of ER stress in vascular calcification include activation of the unfolded 
protein response (UPR), through unfolded protein sensors such as IRE1. UPR aims to restore 
normal ER function or, if not possible, aims towards apoptosis [89]. It involves a complex 
cascade of chaperone proteins (GRP78 and GRP94), activation of caspases, and induction of 
RUNX2 and OC via transcription factors ATF4 and XBP1s [90-93]. The presence of 
abundant and extremely dilated cisternae of the ER has been reported in PXE fibroblasts, as 
well as slightly modified GRP78 proteins [94-96]. Though this was suggestive for an 
involvement of ER stress, no significant change in expression level of ER stress markers 
previously implicated in vascular calcification (CHOP, IRE1, XBP1, ATF4 and ATF6) was 
noted in PXE fibroblast [97]. Based on this, we would conclude that ER stress does not play a 
major role in the PXE pathogenesis. 
It is well known from calcified vasculopathies that an increased rate of apoptosis and 
apoptotic bodies function as a nidus for calcification [28]. Recent data have suggested that 
BMP2 and RUNX2 are pro-apoptotic factors [98,99]. The involved mechanisms depend on 
the cell-type. In soft tissue cells, they include downregulation of BCL-2, accumulation of 
cell-cycle arrest marker P21 and direct activation of Caspase 3, 8 and 9 [53,98,100]. In 
addition, increased levels of P and Ca2+, and oxidative stress also have a major role in 
apoptosis mediated soft tissue calcification [86,101]. On TUNEL staining for in situ cell 
death, PXE fibroblasts reveal a marked increase of apoptosis compared to controls. Apoptosis 
has never been reported in PXE, though the relation between Abcc6 deficiency and cell death 
has been reported in Abcc6 deficient mice with increased cardiac apoptosis and upregulation 
of BMP responsive transcription factors pSmad1/5/8 in the heart [37]. Of the three major 
mechanisms, PXE fibroblasts were noted to show a decreased BCL-2 expression and 
activation of Caspase 3 and Caspase 8. However the activity of P21 was not different in PXE 
fibroblasts compared to controls. Similar pro-apoptotic effects downstream of BMP2 were 
noted in pulmonary vascular smooth muscle cells [102,103]. There, BMP2 had the ability to 
increase caspase activity either directly or via RUNX2 [104,105]. The observation in PXE 
tissues that co-localization of Caspase 3 in mineralized area, and co-localization of RUNX2 
with Caspase 8, suggested an important role for RUNX2 in PXE-related apoptosis. siRNA 
mediated silencing of RUNX2 demonstrated a decrease of apoptosis after 24 and 48 hours, 
though results were variable and apoptosis was still present despite RUNX2 downregulation. 
Though we did not achieve a complete siRNA-induced knockdown of RUNX2, this is in 
favour of a dual BMP2 and BMP2-RUNX2 effect as in other soft tissue cells. Whether other 
pro-apoptotic mechanisms are simultaneously at work in PXE cells remains to be determined. 
Of interest is the observation that TUNEL staining in PXE fibroblasts is primarily present in 
the cytoplasm instead of the nucleus. This might be due to rapid degradation of the nuclear 
membrane due to cell death, though it has also been thought to reflect mitochondrial DNA 
damage [106,107]. As the positive control cells showed nuclear TUNEL staining, we 
consider it unlikely that the labelling in PXE fibroblasts is an artifact. This may further 
corroborate the involvement of mitochondria in the PXE pathophysiology, which was already 
suggested by previously reported ultra-structural and functional abnormalities of the 
mitochondria in PXE as well as the recent report of the presence of the ABCC6 transporter in 
the mitochondria-associated membranes [108,109]. However, further study is needed to 
assess to which extent mitochondrial dysfunction is implicated in the PXE pathogenesis. 
Conclusions 
Our study shows that we cannot simply extrapolate knowledge on cell signalling in vascular 
soft tissue calcification to a multisystem ectopic mineralisation disease such as PXE. 
Contrary, we demonstrate a specific set of perturbed signalling pathways in PXE patients and 
the knock-out mouse model. Based on our findings and literature reports, we propose a 
preliminary cell model of ECM calcification in PXE (Figure 13). In the intricating web of 
calcification inhibitor and propagator signalling, this presents a starting point to further 
unravel the complex cellular signalling in PXE. Besides their relevance for elastic fibre 
mineralization, the pathways that we found disturbed may have a relevance for other features 
of the PXE phenotype, such as neovascularisation. PXE patients often suffer subretinal 
neovascularisation and haemorrhaging as a complication of the PXE retinopathy [110,111]. 
VEGF-A, a potent mediator of angiogenesis, is assumed to play a role in this neo-
angiogenesis, as treatment of PXE patients with anti-VEGF injections has been very 
successful [112]. However, the mechanism behind VEGF-A involvement has not yet been 
uncovered. Runx2 has been described to induce overexpression of Vegf-A and the 
upregulation of Runx2 in Bruch’s membrane of the PXE KO mouse model, may contribute to 
the presence of VEGF-A in the eye [52]. Also, the TGFβ-2 predominance in experimental 
models of choroidal neovascularization may provide further insights in the PXE retinopathy 
[71]. These results may also have implications for future therapies for this as yet intractable 
disease. Curative treatments targeting just one of the biochemical abnormalities in PXE, 
being it e.g. vitamin K deficiency or oxidative stress, might not be sufficient because of their 
synergistic effect [69,70,113]. Conversely, a more central component such as RUNX2 might 
provide a powerful target to influence these different mechanisms, as well as the BMP2 
receptor. Indeed, several small-molecule inhibitors of BMP receptors have been developed 
and mouse models of ectopic mineralization diseases such as Fibrodysplasia Ossificans 
Progressiva, where BMP pathways are deregulated, have already been successfully treated 
with these compounds [114,115]. 
Figure 13 Preliminary cell model of ECM calcification in PXE. PXE fibroblasts reveal 
perturbation of a specific set of signalling pathways including BMP2-SMADs-RUNX2, 
TGFβ-2-SMADs-CTGF, MSX2-Wnt and pERK signalling. Apoptosis seems to be involved 
in PXE mineralization through RUNX2 and BCL-2. Besides the ECM mineralization, some 
of the perturbed signalling molecules, such as RUNX2 and TGFβ-2 can be related to 
neovascularisation, a common process in the complicated PXE retinopathy. 
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labelling in the cytoplasm of the cells is arrowed. Scale bar = 50 µm. 
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RUNX2 siRNA after 24, 48 and 72 hours. siRNA silencing causes a downregulation of 
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fibroblasts (n = 2 cultures). Results are shown after 24, 48 and 72 hours respectively and 
demonstrate a 13 to 20% reduction of apoptosis, though results differ between different cell 
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